Cargando…
Efficacy of lofexidine for mitigating opioid withdrawal symptoms: results from two randomized, placebo-controlled trials
OBJECTIVES: Fear of opioid withdrawal syndrome (OWS) often dissuades opioid discontinuation. Lofexidine is an FDA-approved, alpha(2)-adrenergic receptor agonist for treatment of OWS. Pivotal trial results from the per-protocol statistical analyses have been published. However, the FDA prescribing in...
Autores principales: | Alam, Danesh, Tirado, Carlos, Pirner, Mark, Clinch, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6968526/ https://www.ncbi.nlm.nih.gov/pubmed/32002194 http://dx.doi.org/10.1080/21556660.2019.1704416 |
Ejemplares similares
-
Safety and Efficacy of Lofexidine for Medically Managed Opioid Withdrawal: A Randomized Controlled Clinical Trial
por: Fishman, Marc, et al.
Publicado: (2019) -
Lofexidine for acute opioid withdrawal: A clinical case series
por: Renfro, Mandy L., et al.
Publicado: (2020) -
The Role of Lofexidine in Management of Opioid Withdrawal
por: Pergolizzi, Joseph V., et al.
Publicado: (2018) -
Clinical Efficacy and Safety Profile of Lofexidine Hydrochloride in Treating Opioid Withdrawal Symptoms: A Review of Literature
por: Rehman, Saif Ur, et al.
Publicado: (2019) -
Managing Opioid Withdrawal in an Outpatient Setting With Lofexidine or Clonidine
por: Gripshover, Jeanne, et al.
Publicado: (2022)